Agree with you Sarge.
SB seems a lot more convenient. The Phase 3 study for SB was also quite a bit larger.
SB is also proven in Japanese market, which gives a lot of confidence. Brella doesn't look like it's been on sale yet.
Brella has been known for same some time. I think approved in April this year by FDA? So I would say it's all been factored in by BOT and others.
Like you say, the hastle of having to go to a doc for treatment throughout the year would more of a hastle vs roll on.
Given SBs more robust Phase 3 trial than Brella's which gained approved, I would think that SB approval is almost a certainty.
As confident as ever, but funny how things can come up out that you can miss / don't think about.
Bot Chart, page-6919
-
- There are more pages in this discussion • 6,849 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.3¢ |
Change
-0.018(4.61%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 35.0¢ | $1.830M | 5.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 323044 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 201029 | 4 |
View Market Depth
| Last trade - 10.29am 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |